|
|||||
|
|
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study |
|
| Authors: | Daniel E Meyers MD MSc Benjamin S Meyers BComm Timothy M Chisamore MSc Kristin Wright MD Bishal Gyawali MD PhD Vinay Prasad MD MPH Richard Sullivan MD PhD Christopher M Booth MD |
| Institution: | 1. Department of Medicine, University of Calgary, Calgary, Canada;2. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada;3. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada
Department of Medicine, Queen's University, Kingston, Canada;4. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada Department of Oncology, Queen's University, Kingston, Canada Department of Public Health Sciences, Queen's University, Kingston, Canada;5. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California;6. Institute of Cancer Policy, School of Cancer Sciences, Kings College London, London, United Kingdom |
| Abstract: | |
| Keywords: | cancer economics cancer policy drug revenue financial toxicity health services research health spending |